Filing Details

Accession Number:
0000891839-20-000032
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-27 16:23:22
Reporting Period:
2020-01-23
Accepted Time:
2020-01-27 16:23:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1205922 Vaccinex Inc. VCNX Pharmaceutical Preparations (2834) 161603202
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1747753 Maurice Zauderer C/O Vaccinex, Inc.
1895 Mount Hope Avenue
Rochester NY 14620
President And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-23 98,231 $5.09 1,097,753 No 4 P Indirect By Vaccinex (Rochester), L.L.C.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Vaccinex (Rochester), L.L.C.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 177,748 Direct
Common Stock 213,209 Indirect By Jeremy C. Zauderer Trust
Common Stock 212,161 Indirect By Jordan M. Zauderer Trust
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (Right to Buy) $14.90 2024-03-31 2,589 2,589 Direct
Common Stock Stock Option (Right to Buy) $14.90 2024-06-30 2,589 2,589 Direct
Common Stock Stock Option (Right to Buy) $7.10 2025-12-23 3,325 3,325 Direct
Common Stock Stock Option (Right to Buy) $4.29 2024-03-14 20,000 20,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2024-03-31 2,589 2,589 Direct
2024-06-30 2,589 2,589 Direct
2025-12-23 3,325 3,325 Direct
2024-03-14 20,000 20,000 Direct
Footnotes
  1. Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
  2. Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  3. Exercisable in full as of the date of this report.
  4. This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.